Skip to main content
. 2024 Mar 5;41(7):2991–3002. doi: 10.1007/s12325-024-02810-3

Fig. 1.

Fig. 1

Design of the LIBERTY-BP ADEPT study. A diagram illustrating the LIBERTY-BP ADEPT study design compromised of a screening period (up to 35 days), a treatment period (52 weeks) and a follow-up period (12 weeks). aDupilumab loading dose (or equivalent placebo dose) given at day 1. BL baseline, D1 day 1, EOS end of study, EOT end of treatment, EP endpoint, OCS oral corticosteroids, q2w every 2 weeks, R randomization, SC subcutaneous, W week